What is the efficacy of metronomic chemotherapy following cisplatin (Platinol, cis-diamminedichloroplatinum) treatment for Osteosarcoma (OSA) in canines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Metronomic chemotherapy is recommended as a follow-up treatment after cisplatin for canine osteosarcoma (OSA). A typical protocol involves cyclophosphamide at 10-15 mg/m² daily or every other day, combined with a non-steroidal anti-inflammatory drug (NSAID) such as piroxicam (0.3 mg/kg daily) or meloxicam (0.1 mg/kg daily) 1. This regimen typically begins 2-3 weeks after completing cisplatin therapy and continues long-term, often for 6-12 months or longer if well-tolerated.

Key Considerations

  • Regular monitoring is essential, including complete blood counts every 2-4 weeks initially, then monthly, to check for myelosuppression.
  • Urinalysis should be performed every 1-2 months to monitor for sterile hemorrhagic cystitis, a potential side effect of cyclophosphamide.
  • Metronomic chemotherapy works differently from conventional high-dose chemotherapy by targeting tumor blood vessel formation (anti-angiogenesis) rather than directly killing cancer cells.
  • The combination with NSAIDs enhances anti-angiogenic effects and provides pain control.

Rationale

The most recent and highest quality study, published in 2021, supports the use of metronomic chemotherapy as a follow-up treatment after cisplatin for canine osteosarcoma (OSA) 1. This approach provides continuous low-dose exposure to chemotherapeutic agents, potentially reducing metastasis risk while offering fewer side effects than conventional chemotherapy.

Treatment Protocol

  • Cyclophosphamide: 10-15 mg/m² daily or every other day
  • NSAID: piroxicam (0.3 mg/kg daily) or meloxicam (0.1 mg/kg daily)
  • Monitoring: complete blood counts every 2-4 weeks initially, then monthly; urinalysis every 1-2 months This maintenance therapy is particularly valuable for OSA patients after completing cisplatin, as it may help delay or prevent metastatic disease, which is common in canine OSA even after limb amputation and conventional chemotherapy 1.

From the Research

Metronomic Chemotherapy after Cisplatin Treatment for OSA in Dogs

  • There is no direct evidence in the provided studies regarding metronomic chemotherapy after cisplatin treatment for Osteosarcoma (OSA) in dogs.
  • However, the studies discuss various treatment options for OSA in dogs, including cisplatin and doxorubicin chemotherapy 2, 3, 4, 5, 6.
  • Cisplatin is a commonly used chemotherapy drug for treating OSA in dogs, and it has been shown to improve survival times when used in combination with surgery 4, 5, 6.
  • The use of metronomic chemotherapy, which involves the continuous administration of low-dose chemotherapy, is not mentioned in the provided studies.
  • The studies focus on the use of conventional chemotherapy protocols, such as cisplatin and doxorubicin, to treat OSA in dogs 4, 5, 6.
  • Further research is needed to investigate the efficacy of metronomic chemotherapy after cisplatin treatment for OSA in dogs.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Update on the biology and management of canine osteosarcoma.

The Veterinary clinics of North America. Small animal practice, 2003

Research

What do we know about canine osteosarcoma treatment? Review.

Veterinary research communications, 2015

Research

Limb-sparing treatment for osteosarcoma in dogs.

Journal of the American Veterinary Medical Association, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.